Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Bone Marrow Ribonucleotide Reductase mRNA Levels and Methylation Status As a Prognostic Factor in Patients with Myelodysplastic Syndrome Treated with 5-Azacytidine

Christina-Nefeli Kontandreopoulou, BSc, Panagiotis T Diamantopoulos, MD PhD, Argiris Symeonidis, MD PhD, Ioannis Kotsianidis, Vassiliki Pappa, MD, Athanasios Galanopoulos, MD PhD, Andreas Giannopoulos, BSc, MSc, Katerina Zoi, PhD, Maria Dimou, MD PhD, Elena E. Solomou, MD, Panayiotis Panayiotidis, MD, Georgios Kyriakakis, Nefeli Giannakopoulou, Georgios Dryllis, Sevastianos Chatzidavid, Nora-Athina Viniou, MD PhD

Blood (2019) 134 (Supplement_1): 1721.

https://doi.org/10.1182/blood-2019-126426

Published: 2019

Journal Articles

Metabolic Profiling Identifies De Novo Nucleotide Synthesis As a Potential Metabolic Vulnerability for Targeted Therapy Against Mantle Cell Lymphoma

Yixin Yao, PhD, Yang Liu, PhD, Hui Guo, PhD, Makhdum Ahmed, MD PhD MPH, Shabnam Bhuiyan, MSc, Krystle Nomie, PhD, Liang Zhang, MD PhD, Michael Wang, MD

Blood (2018) 132 (Supplement 1): 2945.

https://doi.org/10.1182/blood-2018-99-112192

Published: 2018

Journal Articles

Targeting Ribonucleotide Reductase M1 and M2 in Multiple Myeloma

Morihiko Sagawa, MD PhD, Hiroto Ohguchi, MD PhD, Takeshi Harada, MD PhD, Mehmet K. Samur, PhD, Yu-Tzu Tai, PhD, Nikhil C Munshi, MD, Teru Hideshima, MD PhD, Kenneth C. Anderson, MD

Blood (2016) 128 (22): 360.

https://doi.org/10.1182/blood.V128.22.360.360

Published: 2016

Journal Articles

Iron Chelation Reinforces DNA Damage Response and Leads to G2/M Checkpoint Activation and Autophagy in Myeloid Bone Marrow Cells of Preleukemia Mouse Model

Leona Raskova Kafkova, Zuzana Somikova, Jana Kucerova, MSc, Lenka Calabkova, Pavla Luzna, Jan Stetka, Dana Simkova, Dalibor Dolezal, Vladimir Divoky, PhD

Blood (2015) 126 (23): 3351.

https://doi.org/10.1182/blood.V126.23.3351.3351

Published: 2015

Journal Articles

RNA-dependent inhibition of ribonucleotide reductase is a major pathway for 5-azacytidine activity in acute myeloid leukemia

Josephine Aimiuwu, Hongyan Wang, Ping Chen, Zhiliang Xie, Jiang Wang, Shujun Liu, Rebecca Klisovic, Alice Mims, William Blum, Guido Marcucci, Kenneth K. Chan

Blood (2012) 119 (22): 5229–5238.

https://doi.org/10.1182/blood-2011-11-382226

Published: 2012

Includes: Supplemental data

Journal Articles

Activity of the Novel Ribonucleotide Reductase Inhibitor Didox on Human and Murine Models of Acute Leukemia,

Guerry J Cook, MSc, Howard L Elford, PhD, Timothy Pardee, MD, PhD

Blood (2011) 118 (21): 3637.

https://doi.org/10.1182/blood.V118.21.3637.3637

Published: 2011

Journal Articles

Regulatory T Cells Enhance the Allogeneic Activity of Endothelial-Specific Cytotoxic T Lymphocytes – Protective Effect of Defibrotide

Guenther Eissner, PhD, Isabel Hartmann, Altug Kesikli, MD, Silvia Haffner, Tanja Sax, Ernst Holler, MD, PhD, Massimo Iacobelli, MD

Blood (2011) 118 (21): 4693.

https://doi.org/10.1182/blood.V118.21.4693.4693

Published: 2011

Journal Articles

Inhibition of Heparinase I by Defibrotide with Potential Clinical Implications.

Jawed Fareed, PhD, Adrian Sonevytsky, BS, Omer Iqbal, MD, Walter P. Jeske, PhD, Massimo Iacobelli, MD, Debra Hoppensteadt, PhD

Blood (2006) 108 (11): 1626.

https://doi.org/10.1182/blood.V108.11.1626.1626

Published: 2006

Journal Articles

Hydroxyurea with Azacitidine or Decitabine in Combination Is Antagonistic on DNA Methylation Inhibition.

Si Ho Choi, MS, Hyang-Min Byun, Ph.D, Jennifer Kwan, BS, Allen S. Yang, MD, Ph.D

Blood (2006) 108 (11): 4303.

https://doi.org/10.1182/blood.V108.11.4303.4303

Published: 2006

Journal Articles

A Phase I Study of GTI-2040, an Antisense to Ribonucleotide Reductase (RNR) in Combination with High-Dose Cytarabine (HiDAC) in Relapsed or Refractory Acute Myeloid Leukemia (AML): Pharmacokinetics (PK), Pharmacodynamic (PD) and Clinical Results.

Rebecca B. Klisovic, W. Blum, X. Wei, S. Liu, C. Kefauver, L. Huynh, J. A. Zwiebel, J. C. Byrd, M. R. Grever, G. Marcucci

Blood (2005) 106 (11): 2790.

https://doi.org/10.1182/blood.V106.11.2790.2790

Published: 2005

Journal Articles

Phase I Study of Triapine® and Cytarabine (ara-C) in Patients with Relapsed or Refractory Acute Leukemias and High-Risk Myelodysplastic Syndrome (MDS).

Karen W.L. Yee, MD, Jorge Cortes, MD, Guillermo Garcia-Manero, MD, Srdan Verstovsek, MD, Alessandra Ferrajoli, MD, William G. Wierda, MD, Deborah Thomas, MD, Stefan Faderl, MD, Ivan King, PhD, Susan M. O’Brien, MD, Mario Sznol, MD, Francis J. Giles, MD

Blood (2005) 106 (11): 4925.

https://doi.org/10.1182/blood.V106.11.4925.4925

Published: 2005

NARROW

Bone Marrow Ribonucleotide Reductase mRNA Levels and Methylation Status As a Prognostic Factor in Patients with Myelodysplastic Syndrome Treated with 5-Azacytidine

Metabolic Profiling Identifies De Novo Nucleotide Synthesis As a Potential Metabolic Vulnerability for Targeted Therapy Against Mantle Cell Lymphoma

Targeting Ribonucleotide Reductase M1 and M2 in Multiple Myeloma

Iron Chelation Reinforces DNA Damage Response and Leads to G2/M Checkpoint Activation and Autophagy in Myeloid Bone Marrow Cells of Preleukemia Mouse Model

RNA-dependent inhibition of ribonucleotide reductase is a major pathway for 5-azacytidine activity in acute myeloid leukemia

Activity of the Novel Ribonucleotide Reductase Inhibitor Didox on Human and Murine Models of Acute Leukemia,

Regulatory T Cells Enhance the Allogeneic Activity of Endothelial-Specific Cytotoxic T Lymphocytes – Protective Effect of Defibrotide

Inhibition of Heparinase I by Defibrotide with Potential Clinical Implications.

Hydroxyurea with Azacitidine or Decitabine in Combination Is Antagonistic on DNA Methylation Inhibition.

A Phase I Study of GTI-2040, an Antisense to Ribonucleotide Reductase (RNR) in Combination with High-Dose Cytarabine (HiDAC) in Relapsed or Refractory Acute Myeloid Leukemia (AML): Pharmacokinetics (PK), Pharmacodynamic (PD) and Clinical Results.

Phase I Study of Triapine® and Cytarabine (ara-C) in Patients with Relapsed or Refractory Acute Leukemias and High-Risk Myelodysplastic Syndrome (MDS).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only